Anrotinib is a multi-targeted, small molecule targeted drug with indications for third-line targeted therapy for non-small cell lung cancer, and also for targeted therapy treatment of soft tissue sarcoma. Treatment can have side effects. Spitting up blood may be due to the targeted drug taking effect, anti-angiogenesis causing tumor shrinkage or tumor necrosis, and blood vessels being stretched and destroyed, which can lead to coughing up blood, requiring hemostatic treatment such as hemostatic aromatic acid to be given. It can also cause gastric ulcers or gastrointestinal bleeding if there are other gastrointestinal reactions. It is necessary to suspend the use of Anrotinib, and then treat with drugs such as hemostatic and stomach acid inhibitors. It is better to do gastroscopy to understand the condition of the digestive tract, and then assess whether the treatment can be continued when the bleeding stops, Anrotinib is more effective in the treatment of advanced tumors.